Phase 2 trial of rogaratinib (pan-FGFR inhibitor) in 24 patients with advanced SDH-deficient GIST achieved a 41.7% objective response rate and 31-month median progression-free survival — the strongest prospective efficacy signal yet reported for this rare disease. The mechanistic basis is that SDH-loss-driven DNA hypermethylation disrupts genomic insulator elements at the FGF3/FGF4 locus, aberrantly activating these ligands and creating an autocrine FGFR1 signaling loop selectively in SDH-deficient tumor cells.

Practical pathology-focused review of the full SDH-deficient tumor spectrum — paraganglioma-pheochromocytoma syndromes (PGL1–5), SDH-deficient GIST, SDH-deficient renal cell carcinoma, Carney-Stratakis syndrome, and Carney triad — with a stepwise diagnostic workflow integrating SDHB/SDHA IHC, morphologic cues, and molecular testing, plus guidance on which cases warrant urgent genetic counseling and family surveillance.

Targeted lipidomics in SDHB-knockdown pheochromocytoma cells revealed distinct baseline ether-phospholipid and sphingomyelin signatures versus wild-type cells; treatment with the polyamine pathway inhibitor DENSPM (N1,N11-diethylnorspermine) induced far greater lipid remodeling and caspase-3-dependent apoptosis in SDHB-deficient cells, suggesting polyamine metabolism as a previously unrecognized SDH-specific metabolic vulnerability.

Comprehensive review synthesizing multi-omics signatures in metastatic PPGL, confirming SDHB-driven pseudohypoxia and CIMP hypermethylation as primary metastatic drivers and cataloguing novel co-occurring alterations: ATRX/TERT mutations, elevated tumor mutational burden, aberrant kynurenine metabolic pathway activity, and an immunosuppressive microenvironment — all emerging as both biomarkers and candidate therapeutic targets.

Comprehensive Endocrine Reviews synthesis of epigenetic regulation across all major neuroendocrine neoplasm types — including detailed coverage of pheochromocytomas and paragangliomas — cataloguing SDHx-driven CIMP hypermethylation, ATRX/TERT alterations governing metastatic risk, histone modification patterns, and non-coding RNA dysregulation as both prognostic markers and therapeutic targets. Reviews methylation-based classifiers and circulating epigenetic biomarkers as emerging precision tools, and covers DNA methyltransferase inhibitors, HDAC inhibitors, and RNA-modifying enzyme modulators under active investigation in neuroendocrine malignancies.

Genome-wide CRISPR-Cas9 synthetic lethality screen in immortalized SDHB-deficient chromaffin cells identified the neddylation pathway — specifically the ubiquitin-conjugating enzyme UBE2F — as a selective vulnerability absent in normal cells. Neddylation inhibitors pevonedistat (MLN4924) and HA-9104 preferentially suppressed growth of SDHB-deficient cells, nominating the cullin-RING ligase neddylation axis as a new, unbiased drug target.

Retrospective series of 9 patients with metastatic SDH-deficient GIST who underwent complete (CC-0) cytoreductive surgery showed a median time to recurrence of 26.1 months post-CRS versus 3.4 months on the last systemic therapy before surgery. While the sample is small and patient selection was stringent, the data suggest surgical debulking may offer meaningful disease control where systemic options have exhausted.

IHC study of 57 SDH-related tumors (paraganglioma, pheochromocytoma, RCC, GIST, seminoma) from patients with confirmed germline SDH pathogenic variants found that 49% showed aberrant retained SDHB staining — divided into four atypical patterns including fine granular blush and focal retention — underscoring that SDHB IHC loss alone cannot exclude SDH deficiency and that any amount of abnormal staining should prompt genetic testing.

Systematic functional screening of somatostatin receptor agonists in SDHB-knockdown versus wild-type pheochromocytoma/paraganglioma cell lines found that SDHB-deficient cells exhibit stronger membrane SSTR2 expression and receptor internalization, and that the selective SSTR2-full agonist BIM-23120 — but not octreotide or pasireotide — selectively reduced proliferation and induced apoptosis in SDHB-deficient cells by dephosphorylating pro-survival kinase cascades. Providing a mechanistic explanation for why cold somatostatin analogs have historically failed in PPGL clinical trials while PRRT (which relies on SSTR2 binding) succeeds: SDHB deficiency specifically sensitizes tumor cells to SSTR2 full agonism, identifying this receptor subtype as a selective pharmacological vulnerability in the SDHB-deficient subset.

Contemporary MD Anderson clinical review providing a genotype-directed treatment algorithm for metastatic pheochromocytoma and paraganglioma (MPPGL), integrating belzutifan (recently FDA-approved for MPPGL), sunitinib, cabozantinib, radiopharmaceuticals (131I-MIBG, 177Lu-DOTATATE), and chemotherapy into a clinical decision framework based on SDHx and other genotypes, catecholamine phenotype, and tumor burden. The most current comprehensive guidance for matching systemic therapy to individual patient genotype in advanced PPGL.